Biolinerx Teams with Jiangsu for Hepatitis C Drug in China
SHANGHAI, China – A licensing agreement may help troubled Israeli Biolinerx Ltd. get a toehold in China with its HCV treatment BL-8030. In a deal worth as much as $30 million in initial and milestone payments, Biolinerx entered an agreement for the development, manufacture and commercialization of BL-8030 with liver therapy specialist Jiangsu Chia-tai Tianqing Pharmaceutical Co. Ltd.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST